{
  "resourceType" : "ValueSet",
  "id" : "HIV.C.DE17",
  "meta" : {
    "profile" : ["http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareablevalueset",
    "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishablevalueset",
    "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-computablevalueset"]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ValueSet HIV.C.DE17</b></p><a name=\"HIV.C.DE17\"> </a><a name=\"hcHIV.C.DE17\"> </a><a name=\"hcHIV.C.DE17-en-US\"> </a><ul><li>Include these codes as defined in <a href=\"CodeSystem-HIVConcepts.html\"><code>http://smart.who.int/hiv/CodeSystem/HIVConcepts</code></a><table class=\"none\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46C.46DE18\">HIV.C.DE18</a></td><td>TDF + FTC</td><td>Treated with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46C.46DE19\">HIV.C.DE19</a></td><td>TDF</td><td>Treated with single-agent tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46C.46DE20\">HIV.C.DE20</a></td><td>TDF + 3TC</td><td>Treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46C.46DE21\">HIV.C.DE21</a></td><td>Other TDF-based regimen</td><td>Treated with other tenofovir disoproxil fumarate (TDF)-based regimen (oral PrEP)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46C.46DE22\">HIV.C.DE22</a></td><td>Dapivirine vaginal ring (DVR)</td><td>Dapivirine vaginal ring (DVR) for HIV prevention</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46C.46DE23\">HIV.C.DE23</a></td><td>CAB-LA</td><td>Long-acting injectable cabotegravir</td></tr></table></li></ul></div>"
  },
  "url" : "http://smart.who.int/hiv/ValueSet/HIV.C.DE17",
  "version" : "0.1.0",
  "name" : "HIVCDE17",
  "title" : "Current PrEP regimen ValueSet",
  "status" : "active",
  "experimental" : true,
  "date" : "2024-07-01T05:12:03+00:00",
  "publisher" : "WHO",
  "contact" : [{
    "name" : "WHO",
    "telecom" : [{
      "system" : "url",
      "value" : "http://who.int"
    }]
  }],
  "description" : "Value set of HIV pre-exposure prophylaxis (PrEP) regimen",
  "compose" : {
    "include" : [{
      "system" : "http://smart.who.int/hiv/CodeSystem/HIVConcepts",
      "concept" : [{
        "code" : "HIV.C.DE18",
        "display" : "TDF + FTC"
      },
      {
        "code" : "HIV.C.DE19",
        "display" : "TDF"
      },
      {
        "code" : "HIV.C.DE20",
        "display" : "TDF + 3TC"
      },
      {
        "code" : "HIV.C.DE21",
        "display" : "Other TDF-based regimen"
      },
      {
        "code" : "HIV.C.DE22",
        "display" : "Dapivirine vaginal ring (DVR)"
      },
      {
        "code" : "HIV.C.DE23",
        "display" : "CAB-LA"
      }]
    }]
  }
}